When was GNA Biosolutions founded?

GNA Biosolutions was founded in 2010 and raised its 1st funding round 5 years after it was founded.

Where is GNA Biosolutions located?

GNA Biosolutions is headquartered in Planegg, Germany.

Which legal entities is GNA Biosolutions associated with?

GNA Biosolutions is associated with Gna Biosolutions Gmbh and 1 other.

How many employees does GNA Biosolutions have?

As of May 31, 2026, the latest employee count at GNA Biosolutions is 8.

Is GNA Biosolutions a funded company?

GNA Biosolutions is a funded company, having raised a total of $20.2M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jun 19, 2015.

When was the latest funding round of GNA Biosolutions?

GNA Biosolutions' latest funding was a $***** Series C round on Aug 05, 2019, with participation from 9 investors.

Where does GNA Biosolutions rank among its competitors?

GNA Biosolutions ranks 36th amongst 249 active competitors, of which 75 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Nanopore Technologies, which secured $64.2M in Aug, 2024.

Who are the top competitors of GNA Biosolutions?

GNA Biosolutions' top competitors include Nanopore Technologies, PacBio and OpGen. Among them, Nanopore Technologies secured the most recent funding round in August, 2024.

GNA Biosolutions - 2026 Company Profile, Team, Funding, Competitors & Financials

GNA Biosolutions is a series C company based in Planegg (Germany), founded in 2010. It operates as a Develops instruments, OEM modules and assays for molecular pathogen detection. GNA Biosolutions has raised $20.2M in funding from investors like Bayern Kapital, GreyBird Ventures and OCCIDENT. The company has 249 active competitors, including 75 funded and 41 that have exited. Its top competitors include companies like Nanopore Technologies, PacBio and OpGen.

Company Details

Develops instruments, OEM modules and assays for molecular pathogen detection. It claims its technology as a new approach to PCR along with cooling and heating rates at different orders and enables physicians and hospitals to diagnose bacterial diseases. Its first product Pharos400 features laser-based PCR technology is for thermal cycling and fluorescence-free real-time readout of results.

Website: www.gna-bio.com/
Email ID: *****@gna-bio.com

Key Metrics

Founded Year

2010

Location

Planegg, Germany

Stage

Series C

Total Funding

$20.2M in 3 rounds

Latest Funding Round

Series C, Aug 05, 2019, $*****

Investors

Bayern Kapital & 12 more

Ranked

36^th among 249 active competitors

Employee Count

8 as on May 31, 2026

Similar Companies

Nanopore Technologies & 270 more

View GNA Biosolutions' full profile

GNA Biosolutions is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Hp Health Solutions Germany Gmbh CIN: HRB186540 , Germany, Active	Jul 01, 2010	-	-
Gna Biosolutions Gmbh CIN: HRB186540. , Germany, Active	Jul 01, 2010	-	29 (As on Dec 31, 2020)

GNA Biosolutions has raised a total funding of $20.2M over 3 rounds. Its first funding round was on Jun 19, 2015. Its latest funding round was a Series C round on Aug 05, 2019 for $*****. 9 investors participated in its latest round. GNA Biosolutions has 13 institutional investors.

Here is the list of recent funding rounds of GNA Biosolutions:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 05, 2019	3863355	Series C	3450160	1620106	9310486	6260699
Dec 01, 2017	4476552	Grant (prize money)	3175980	6134467	3278550	Europa
Jun 19, 2015	9161991	Series B	2760189	8397772	8669172	Kfw & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of GNA Biosolutions's funding rounds and investors

GNA Biosolutions' Board of Directors

GNA Biosolutions's board has 3 active members. Lars Ullerich, Joachim Stehr and Federico Buersgens are part of team.

Here is the list of GNA Biosolutions' board of directors:

Name	Type	Representing	Status	Duration
Lars Ullerich	Team	-	Current	16y 0m
Joachim Stehr	Team	-	Current	16y 0m
Federico Buersgens	Team	-	Current	16y 0m
cdeamvd	Team	-	Past	8y 6m

GNA Biosolutions' employee count trend

GNA Biosolutions has 8 employees as of May 26. Here is GNA Biosolutions's employee count trend over the years:

Employee count trend for GNA Biosolutions

Uncover GNA Biosolutions' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GNA Biosolutions include Nanopore Technologies, PacBio and OpGen. Here is the list of Top 10 competitors of GNA Biosolutions, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nanopore Technologies 2005, Oxford (United Kingdom), Public	Manufacturer of portable and benchtop devices for real-time DNA sequencing	$1.26B	IP Group, GIC & 91 others	75/100
2nd	PacBio 2004, Menlo Park (United States), Public	Developer of instrument systems and software for real-time sequencing of single-molecules	$410M	Deerfield, Maverick Capital & 24 others	72/100
3rd	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	67/100
4th	Complete Genomics 2006, San Jose (United States), Acquired	Developer of DNA sequencing platform for human genome sequencing and analysis	$125M	Enterprise Partners Venture Capital, Orbimed ... & 8 others	66/100
5th	Ultima Genomics 2016, Newark (United States), Series D	Developer of high-throughput NGS instrument for research	$600M	Andreessen Horowitz, Founders Fund & 8 others	62/100
6th	Singular Genomics 2016, San Diego (United States), Acquired	Provider of next-generation gene sequencing and multi-omics technologies	-	Perceptive Advisors, Domain Associates & 5 others	60/100
7th	Omniome 2013, San Diego (United States), Acquired	Provider of genome sequencing platform	$160M	Decheng Capital, Hillhouse & 12 others	59/100
8th	S2 Genomics 2016, Livermore (United States), Acquired	Developer of automated sample preparation systems for genomics	$16M	RCT, Broadoak Capital Partners & 6 others	59/100
9th	Bionano 2002, San Diego (United States), Public	Provider of genome analysis solutions to researchers and clinicians	$124M	Battelle Ventures, Domain Associates & 17 others	58/100
10th	ReadCoor 2016, Cambridge (United States), Acquired	Innovating single-cell, spatial, and in situ biology tools for researchers	$55.6M	Decheng Capital, Pavilion Capital Partners ... & 6 others	56/100
36th	GNA Biosolutions 2010, Planegg (Germany), Series C	Develops instruments, OEM modules and assays for molecular pathogen detection	$20.2M	b2venture, Robert Bosch Venture Capital & 11 others	41/100